EMA validates Soleno’s application for Prader-Willi syndrome treatment
The EMA has validated the MAA submitted by Soleno Therapeutics for diazoxide choline prolonged-release tablets for Prader-Willi syndrome.
The EMA has validated the MAA submitted by Soleno Therapeutics for diazoxide choline prolonged-release tablets for Prader-Willi syndrome.
What's Your Reaction?
